| 1 |
Castilloux J, Laberge AM, Martin SR, et al. " Silent" tyrosinemia presenting as hepatocellular carcinoma in a 10-year-old girl [J]. J Pediatr Gastroenterol Nutr, 2007, 44(3):375-377.
|
| 2 |
Chinsky JM, Singh R, Ficicioglu C, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations [J]. Genet Med, 2017, 19(12).
|
| 3 |
Mohan N, McKiernan P, Preece MA, et al. Indications and outcome of liver transplantation in tyrosinaemia type 1 [J]. Eur J Pediatr, 1999, 158(Suppl 2):S49-S54.
|
| 4 |
Arnon R, Annunziato R, Miloh T, et al. Liver transplantation for hereditary tyrosinemia type I: analysis of the UNOS database [J]. Pediatr Transplant, 2011, 15(4):400-405.
|
| 5 |
Linblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tytosinemia [J]. Proc Natl Acad Sci USA, 1977, 74(10):4641-4645.
|
| 6 |
Kitagawa T. Hepatorenal tyrosinemia [J]. Proc Jpn Acad Ser B Phys Biol Sci, 2012, 88(5):192-200.
|
| 7 |
Mitchell G, Larochelle J, Lambert M, et al. Neurologic crises in hereditary tyrosinemia [J]. N Engl J Med, 1990, 322(7):432-437.
|
| 8 |
van Spronsen FJ, Thomasse Y, Smit GP, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment [J]. Hepatology, 1994, 20(5):1187-1191.
|
| 9 |
Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase [J]. Lancet, 1992, 340(8823):813-817.
|
| 10 |
McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1[J]. Drugs, 2006, 66(6):743-750.
|
| 11 |
Holme E, Lindstedt S. Nontransplant treatment of tyrosinemia [J]. Clin Liver Dis, 2000, 4(4):805-814.
|
| 12 |
Mowat AP. Liver disorders in children: the indications for liver replacement in parenchymal and metabolic diseases[J]. Transplant Proc, 1987, 19(4):3236-3241.
|
| 13 |
Shneider BL, Vockley J, Mazariegos GV. Trading places: liver transplantation as a treatment, not a cure, for metabolic liver disease [J]. Liver Transpl, 2011, 17(6):628-630.
|
| 14 |
Kasahara M, Sakamoto S, Horikawa R, et al. Living donor liver transplantation for pediatric patients with metabolic disorders: the Japanese multicenter registry [J]. Pediatr Transplant, 2014, 18(1):6-15.
|
| 15 |
Maiorana A, Malamisura M, Emma F, et al. Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1[J]. Mol Genet Metab, 2014, 113(3):188-193.
|
| 16 |
Bartlett DC, Preece MA, Holme E, et al. Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1[J]. J Inherit Metab Dis, 2013, 36(1):15-20.
|
| 17 |
Oishi K, Arnon R, Wasserstein MP, et al. Liver transplantation for pediatric inherited metabolic disorders: Considerations for indications, complications, and perioperative management[J]. Pediatr Transplant, 2016, 20(6):756-769.
|
| 18 |
Kloesel B, Holzman RS. Anesthetic management of patients with inborn errors of metabolism[J]. Anesth Analg, 2017, 125(3):822-836.
|
| 19 |
Ozturk L, Kesimci E, Albayrak T, et al. Sevoflurane in anaesthetic management of a patient with methylmalonic acidaemia[J]. Eur J Anaesthesiol, 2011, 28(2):142-145.
|
| 20 |
Niezgoda J, Morgan PG. Anesthetic considerations in patients with mitochondrial defects[J]. Paediatr Anaesth, 2013, 23(9):785-793.
|
| 21 |
Harker HE, Emhardt JD, Hainline BE. Propionic academia in a four-month-old male: a case study and anesthetic implications[J]. Anesth Analg, 2000, 91(2):309-311.
|
| 22 |
Gurrieri C, Kivela JE, Bojanić K, et al. Anesthetic considerations in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome: a case series [J]. Can J Anaesth, 2011, 58(8):751-763.
|
| 23 |
Savard M, Dupré N, Turgeon AF, et al. Propofol-related infusion syndrome heralding a mitochondrial disease: case report [J]. Neurology, 2013, 81(8):770-771.
|